Oraya Therapeutics Inc. announced today that leading ophthalmologists from three European countries presented patient results following one year after a single treatment with Oraya Therapy for wet age-related macular degeneration (AMD), during a symposium at the European Society of Retina Specialists’ 15th Congress in Nice, France. The results show that Oraya Therapy is effective in maintaining vision with reduced injections for patients at different stages of their disease—from chronic patients in discontinuous treatment to treatment-naive patients with new diagnosis—and following different treatment pathways.

Chronic patients treated with Oraya Therapy maintained vision with less fluid in the macula and fewer injections compared to same-patient history. These patients experienced a significant 40 percent to 74 percent reduction in the number of injections required to maintain vision compared to their previous injection needs, with a corresponding significant decrease in macular oedema characterized by a decrease in central macular thickness. Patients were offered Oraya Therapy if they met the responder profile from the INTREPID sham-controlled masked study of Oraya Therapy adjunctive to anti-VEGF for treating wet AMD.

Oraya Therapy Stereotactic Radiotherapy delivers highly targeted, low-energy X-rays to the diseased area of the eye and is intended as a one-time outpatient procedure. The rationale for the use of Oraya Therapy adjunctive to anti-VEGF therapy was reviewed by Professor Frank Zimmerman from the University of Basel, Switzerland. “The dose of 16 Gy delivered in one session with high precision—as is done with the IRay® radiotherapy system—is in the optimal range to act synergistically with existing anti-VEGF treatments to counter proliferation of the neovascular lesion,” Zimmerman said. “The precision with which the X-ray is directed at a very small volume of tissue is a new aspect to this treatment, resulting in a strong biological effect with a high degree of safety.”